<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="35808">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02640404</url>
  </required_header>
  <id_info>
    <org_study_id>MTA90</org_study_id>
    <secondary_id>U1111-1143-9207</secondary_id>
    <nct_id>NCT02640404</nct_id>
  </id_info>
  <brief_title>Safety of a Meningococcal (Groups A, C, Y and W-135) Polysaccharide Diphtheria Toxoid Conjugate Vaccine in Healthy Subjects in Vietnam</brief_title>
  <official_title>Safety of a Meningococcal (Groups A, C, Y and W-135) Polysaccharide Diphtheria Toxoid Conjugate Vaccine (Menactra®) in Healthy Subjects Aged 9 Months to 55 Years in Vietnam</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sanofi Pasteur, a Sanofi Company</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sanofi</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of the study is to assess the safety of Menactra vaccine in infants, toddlers,
      children, adolescents, and adults

      Objective:

        -  To describe the safety profile after each and any dose (when applicable) of Menactra
           vaccine in participants aged 9 months to 55 years for registration.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Infants and toddlers will receive 2 doses of vaccine 3 months apart. Children ≥ 2 years
      through adults aged 55 years will receive a single dose of vaccine. All participants will be
      evaluated for safety up to 28 days post-vaccination
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>June 2016</start_date>
  <completion_date type="Anticipated">December 2017</completion_date>
  <primary_completion_date type="Anticipated">April 2017</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Open Label</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of participants reporting solicited injection site reactions, solicited systemic reactions, unsolicited adverse events, and serious adverse events occurring during trial</measure>
    <time_frame>Day 0 up to Day 28 post-vaccination</time_frame>
    <description>Solicited injection site reactions: Tenderness/Pain, Erythema, and Swelling. Solicited systemic reactions: infants and toddlers (9 to 23 months) Fever (temperature), Vomiting, Abnormal crying, Drowsiness, Loss of appetite and Irritability; Subjects aged 2 to 55 years, Fever (temperature), Headache, Malaise, and Myalgia</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">224</enrollment>
  <condition>Meningitis</condition>
  <condition>Meningococcal Meningitis</condition>
  <condition>Meningococcal Infections</condition>
  <arm_group>
    <arm_group_label>Menactra Group 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Infants and toddlers participants aged 9 to 23 months will receive 2 doses of Menactra vaccine</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Menactra Group 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants aged 2 to 55 years will receive 1 dose of Menactra vaccine</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Meningococcal (Groups A, C, Y and W-135) Polysaccharide Diphtheria Toxoid Conjugate Vaccine</intervention_name>
    <description>0.5 mL, Intramuscular. 2 doses 3 months apart</description>
    <arm_group_label>Menactra Group 1</arm_group_label>
    <other_name>Menactra®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Meningococcal (Groups A, C, Y and W-135) Polysaccharide Diphtheria Toxoid Conjugate Vaccine</intervention_name>
    <description>0.5 mL, Intramuscular.</description>
    <arm_group_label>Menactra Group 2</arm_group_label>
    <other_name>Menactra®</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Aged 9 months to 55 years on the day of the first study visit

          -  For adults: Informed consent form has been signed and dated by the subject. For
             minors: Informed consent form has been signed and dated by the parent or legally
             acceptable representative. In addition, in accordance with the Independent Ethics
             Committee /Institutional Review Board requirements and as appropriate for the age of
             the subject, the subject may be required to sign and date the informed consent form
             if aged 12 to 17 years or assent form if aged 8 to 11 years.

          -  Subject and/or parent/legally acceptable representative (if applicable) are able to
             attend all scheduled visits and to comply with all study procedures.

        Exclusion Criteria:

          -  Participation at the time of study enrollment (or in the 4 weeks preceding study
             vaccination) or planned participation during the present study period in another
             clinical study investigating a vaccine, drug, medical device, or medical procedure

          -  Receipt of any vaccine in the 4 weeks preceding the study vaccination or planned
             receipt of any vaccine in the 4 weeks following study vaccination.

          -  Known or suspected congenital or acquired immunodeficiency; or receipt of
             immunosuppressive therapy, such as anti-cancer chemotherapy or radiation therapy,
             within the preceding 6 months; or long-term systemic corticosteroid therapy (≥
             2mg/kg/day prednisone or equivalent for more than 2 consecutive weeks within the past
             3 months)

          -  Known systemic hypersensitivity to any of the vaccine components, or history of a
             life-threatening reaction to the vaccine used in the study or to a vaccine containing
             any of the same substances

          -  Laboratory-confirmed, self-reported, or known (as reported by the parent/legally
             acceptable representative) thrombocytopenia, contraindicating intramuscular
             vaccination

          -  Bleeding disorder, or receipt of anticoagulants in the 3 weeks preceding inclusion,
             contraindicating intramuscular vaccination

          -  Personal history of Guillain-Barré syndrome

          -  Chronic illness that, in the opinion of the investigator, is at a stage where it
             might interfere with study conduct or completion

          -  Moderate or severe acute illness/infection (according to investigator judgment) on
             the day of vaccination or febrile illness (temperature ≥ 37.5°C or ≤ 35.5°C). A
             prospective subject should not be included in the study until the condition has
             resolved or the febrile event has subsided.

          -  Identified as a natural or adopted child of the Investigator or employee with direct
             involvement in the proposed study, or identified as an immediate family member (i.e.,
             parent, spouse, natural or adopted child) of the Investigator or employee with direct
             involvement in the proposed study

          -  Subject is pregnant, or lactating, or of childbearing potential (to be considered of
             non-childbearing potential, a female must be pre-menarche or post-menopausal for at
             least 1 year, surgically sterile, or using an effective method of contraception or
             abstinence from at least 4 weeks prior to vaccination and until at least 4 weeks
             after vaccination)

          -  Deprived of freedom by an administrative or court order, or in an emergency setting,
             or hospitalized involuntarily

          -  Current alcohol abuse or drug addiction
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>9 Months</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Director</last_name>
    <role>Study Director</role>
    <affiliation>Sanofi Pasteur Asia Pacific</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Public Registry Sanofi Pasteur</last_name>
    <email>RegistryContactUs@sanofipasteur.com</email>
  </overall_contact>
  <location>
    <facility>
      <address>
        <city>Vinh Long City</city>
        <state>Vinh Long Province</state>
        <country>Vietnam</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Vietnam</country>
  </location_countries>
  <link>
    <url>http://www.sanofipasteur.com</url>
  </link>
  <link>
    <url>http://www.sanofi.com</url>
  </link>
  <verification_date>June 2016</verification_date>
  <lastchanged_date>June 6, 2016</lastchanged_date>
  <firstreceived_date>December 22, 2015</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Meningitis</keyword>
  <keyword>Meningococcal Meningitis</keyword>
  <keyword>Meningococcal Infections</keyword>
  <keyword>Menactra®</keyword>
  <keyword>Meningococcal Vaccine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Meningitis</mesh_term>
    <mesh_term>Diphtheria</mesh_term>
    <mesh_term>Meningitis, Meningococcal</mesh_term>
    <mesh_term>Meningococcal Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
